GLP-1 Research Stack: Semaglutide + Cagrilintide Protocol | QSC Peptides
QSC RESEARCH STACK PROTOCOL
GLP-1 Research Stack: Semaglutide + Cagrilintide Research Protocol
Semaglutide + cagrilintide (CagriSema in clinical development) is the most studied dual-mechanism obesity research combination. Semaglutide activates GLP-1R (appetite/gastric emptying); cagrilintide activates amylin receptor (area postrema satiety). The two compounds act on completely different satiety pathways — enabling mechanistic dissection of GLP-1R vs amylin contributions to appetite regulation.
Semaglutide 30 nmol/kg SC + cagrilintide 10-30 nmol/kg SC vs each alone and vehicle in DIO mice. Acute food intake (0-4hr, 4-8hr, 8-24hr post-injection), body weight, gastric emptying (acetaminophen absorption), plasma GLP-1/amylin levels.
2. Chronic DIO weight loss study
Semaglutide 30 nmol/kg SC 3x/week + cagrilintide 30 nmol/kg SC 3x/week × 8 weeks in DIO C57BL/6. Body weight (daily), food intake (daily), EchoMRI fat/lean mass (weeks 0/4/8), GTT/ITT (week 6), plasma insulin/GLP-1/leptin, liver histology.
3. Mechanistic receptor dissection
CagriSema combination ± exendin 9-39 (GLP-1R antagonist) ± AC187 (amylin receptor antagonist). 2×2 factorial: identifies which effects are GLP-1R-mediated, which are amylin-mediated, and which require both. Key for understanding the synergy mechanism.
4. CNS activation (c-Fos mapping)
Single dose semaglutide + cagrilintide vs each alone. Brain c-Fos IHC at 2hr: ARC (appetite regulation), NTS (vagal satiety), area postrema (amylin primary target), PVN (energy balance). Identifies differential CNS activation patterns of GLP-1R vs amylin pathways.
Why this combination?
GLP-1R and amylin receptors activate distinct satiety pathways. GLP-1R signals primarily through the ARC and NTS (gut-brain vagal axis). Amylin acts primarily on the area postrema and adjacent brainstem nuclei. These two signals converge at the PVN but through independent ascending pathways. The combination produces satiety signals that are additive or synergistic — explaining why CagriSema in Phase 3 trials (CagriSema OASIS) produces substantially greater weight reduction than semaglutide alone (up to 25% in some trial arms).
❓
Frequently Asked Questions
What is cagrilintide and how does it differ from amylin?
Cagrilintide is a long-acting amylin analogue with a fatty acid conjugation that extends its half-life to ~7 days (weekly dosing). Natural amylin has a short half-life. Cagrilintide activates amylin receptors (CALCR + RAMP1/2/3) at the area postrema and hypothalamus — producing sustained satiety signalling that complements GLP-1R action.
Why does semaglutide + cagrilintide outperform semaglutide alone?
The two compounds activate distinct satiety circuits. GLP-1R acts primarily through ARC/NTS; amylin acts primarily through area postrema. Combining two independent satiety signals produces additive/synergistic appetite suppression — explaining the greater weight reduction vs semaglutide monotherapy in clinical trials.
What are the primary endpoints for semaglutide + cagrilintide research?
Body weight (primary), fat mass (EchoMRI), food intake, glucose tolerance (GTT), insulin sensitivity (ITT/HOMA-IR), and CNS activation markers (c-Fos IHC in ARC/NTS/area postrema). Mechanistic studies should include receptor antagonist arms to isolate GLP-1R vs amylin contributions.
